Mounjaro and Wegovy Reimbursed in France, What Changes

Since 15 June 2026, Wegovy and Mounjaro are reimbursed in France under specific medical conditions, which makes GLP-1 treatment far more accessible than when it was fully out of pocket. Reimbursement lowers the cost barrier, but it does not change the nutrition work that decides whether the treatment actually helps.

Reimbursement in France typically comes with eligibility criteria tied to body mass index and related health conditions, and it usually requires medical follow-up rather than free access for anyone. The practical effect is that more people who genuinely qualify can start treatment, and more will stay on it long enough to need a real eating strategy.

Wider access also means more first-time users hitting the same early hurdles. Smaller appetite, nausea around dose changes and the risk of losing muscle if protein stays too low. Knowing this before you start saves weeks of trial and error and protects the results the medication is meant to deliver.

The nutrition priorities do not change because the cost did. Put protein first, aim for roughly 1.2 to 1.6 grams per kilo of body weight, keep meals small and frequent, favor vegetables and slow carbs, and drink water steadily since thirst gets blunted. Go easy on fried, very greasy and very sugary food, the usual triggers for nausea.

Reimbursement is good news, but the medication is a tool, not a cure on its own. The people who keep the weight off are the ones who build sustainable eating habits while they are on it, so the food side is worth as much attention as the prescription itself.

If wider access means you are starting treatment, Mello makes the food side simple from day one. Snap a photo of any meal for instant calories and protein, get a GLP-1 friendly score so you know whether a plate fits, and track your weekly dose right next to your meals. Download Mello to start your GLP-1 journey on the right foot.